Zolpidem Tapering Protocol

Introduction to Tapering

A gradual taper of zolpidem at a rate of 10% per month or slower is recommended to minimize withdrawal symptoms and ensure patient safety, as suggested by the Centers for Disease Control and Prevention 1, 2

For patients who have been taking zolpidem long-term (≥1 year), a slow taper of 10% per month or slower is better tolerated than more rapid tapers, according to the Centers for Disease Control and Prevention 1
For shorter-term use, a taper reducing weekly dosage by 10-25% of the original dosage may be appropriate, as recommended by the Centers for Disease Control and Prevention 2, 3
The taper should be individualized based on duration of previous zolpidem therapy, current dosage, and patient's tolerance of the taper, as suggested by the Centers for Disease Control and Prevention 1 and the American Academy of Sleep Medicine 4

Evaluate current zolpidem dosage (typically 5-10mg for immediate release or 6.25-12.5mg for extended release) and determine duration of use, as recommended by the American Academy of Sleep Medicine 4, 5
For standard immediate-release zolpidem (10mg), reduce by 1.25-2.5mg every 1-2 weeks, as suggested by the Centers for Disease Control and Prevention 2
For extended-release zolpidem (12.5mg), reduce by 3.125mg (1/4 tablet) every 2-4 weeks, as recommended by the American Academy of Sleep Medicine 5, 6

Monitor for withdrawal symptoms including anxiety, insomnia, abdominal pain, vomiting, diarrhea, diaphoresis, tremor, and tachycardia, as recommended by the Centers for Disease Control and Prevention 1, 3
If clinically significant withdrawal symptoms occur, slow the taper rate further, as suggested by the Centers for Disease Control and Prevention 1

Maximize non-pharmacologic sleep interventions, including sleep hygiene education, cognitive behavioral therapy for insomnia (CBT-I), and regular sleep schedule, as recommended by the American Academy of Sleep Medicine 4, 5, 7, 8
Consider alternative pharmacologic options if needed, such as low-dose sedating antidepressants (e.g., trazodone) for temporary support, as suggested by the American Academy of Sleep Medicine 4

Avoid concurrent use with benzodiazepines due to increased risk of respiratory depression and overdose, as recommended by the Centers for Disease Control and Prevention 2
Patients with a history of substance use disorder may require more gradual tapering and additional support, as suggested by the Centers for Disease Control and Prevention 1
Elderly patients typically require lower doses and more gradual tapering schedules, as recommended by the American Academy of Sleep Medicine 4

Follow up at least monthly with patients during the tapering process, as recommended by the Centers for Disease Control and Prevention 1
If tapering fails, reassess the approach and consider a slower taper rate, as suggested by the Centers for Disease Control and Prevention 1

Abrupt discontinuation can lead to rebound insomnia and withdrawal symptoms similar to benzodiazepines, as warned by the American Academy of Sleep Medicine 4
Tapering too quickly can lead to withdrawal symptoms that may be mistaken for return of the original insomnia, as cautioned by the Centers for Disease Control and Prevention 1
Advise patients of increased risk for overdose if they return to their previous higher dose after significant tapering, as recommended by the Centers for Disease Control and Prevention 1, 3

The American Academy of Sleep Medicine recommends maximizing non-pharmacologic interventions throughout the taper, including Cognitive Behavioral Therapy for Insomnia (CBT-I) as first-line adjunctive treatment, sleep hygiene education, and regular sleep schedule maintenance 9
The American Academy of Sleep Medicine suggests considering temporary addition of trazodone 25-100 mg or doxepin 3-6 mg if insomnia worsens significantly during taper 9

The Mayo Clinic recommends documenting the tapering plan thoroughly, including rationale, patient education provided, and monitoring schedule 10